Genmab — Juni 2020
-
Byd endelig ind, hvis der er nogen som sidder inde med den aktuelle analyse.
-
Skal de fleste aktier ikke det?
-
Det kommer vi ikke uden om.

-
Det ser vi frem til Exitnu. Nemlig ved at være sidste udkald hvis man vil med på opturen. Forventer retracement vil fortsætte lidt endnu ned mod de 1736 i første omgang og denne retracement kan blive forstærket p.g.a de sure marked og evt. test af modstanden i 1611-1633 niveau såfremt SP500 skal ned og teste modstanden i 2720
-
Brexit har ingen speciel betydning for Genmab.
-
Novo ser også fin ud.
-
It is only a very short data follow up at the moment, on the other hand it is very good data and very early responses, which is particularly important for Amyloidosis in order to prevent organ damage, so maybe that is enough for FDA to accept a filing?
-
Genmab A/S (GMAB) Remains Dominant Post EHA - Suntrust https://www.streetinsider.com/Analyst+Comments/Genmab+AS+(GMAB)+Remains+Dominant+Post+EHA+-+Suntrust/17004986.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind